Novel pyrrolyl-thiazole derivatives

ABSTRACT

The present invention relates to compounds of formula (I)  
                 
 
     wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6  and R 7  are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

BACKGROUND OF THE INVENTION

[0001] The present invention is concerned with novel pyrrolyl-thiazole derivatives, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention may be useful in treating obesity and other disorders.

[0002] Two different subtypes of cannabinoid receptors (CB₁ amd CB₂) have been isolated and both belong to G protein coupled receptor superfamily. An alternative spliced form of CB₁, CB_(1A), has also been described, but it did not exhibit different properties in terms of ligand binding and receptor activation than CB₁ (D. Shire, C. Carrillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, G. Le Fur, D. Caput, P. Ferrara, J. Biol. Chem. 270 (8) (1995) 3726-31). The CB₁, receptor is mainly located in the brain, whereas the CB₂ receptor is predominately distributed in the periphery and primarily localized in spleen and cells of the immune system (S. Munro, K. L. Thomas, M. Abu-Shaar, Nature 365 (1993) 61-61). Therefore in order to avoid side effects a CB1-selective compound is desirable.

[0003] Δ⁹-tetrahydrocannabinol (Δ⁹-THC) is the principal psychoactive compound in the Indian hemp (Y. Gaoni, R. Mechoulam, J. Am. Chem. Soc., 86 (1964) 1646), canabis savita (marijuanan), which is used in medicine since ages (R. Mechoulam (Ed.) in “Cannabinoids as therapeutic Agents”, 1986, pp. 1-20, CRC Press). Δ⁹-THC is a non-selective CB₁/₂ receptor agonist and is available in the USA as dronabinol (marinol®) for the alleviation of cancer chemotherapy-induced emesis (CIE) and the reversal of body weight loss experienced by AIDS patients through appetite stimulation. In the UK Nabolinone (LY-109514, Cesamet®), a synthetic analogue of Δ⁹-THC, is used for CIE (R. G. Pertwee, Pharmaceut. Sci. 3 (11) (1997) 539-545, E. M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314).

[0004] Anandamide (arachidonylethanolamide) was identified as the endogenous ligand (agonist) for the CB₁ receptor (R. G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664; W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Science 258 (1992) 1946-9). Anandamide and 2-arachidonoylglycerol (2-AG) modulate at the presynaptic nerve teminal negatively adenylate cyclase and voltage-sensitive Ca²⁺ channels and activates the inwardly rectifying K⁺ channel (V. Di Marzo, D. Melck, T. Bisogno, L. De Petrocellis, Trends in Neuroscience 21 (12) (1998) 521-8), thereby affecting neurotransmitter release and/or action, which decreases the release of neurotransmitter (A. C. Porter, C. C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60).

[0005] Anandamide as Δ⁹-THC also increases feeding through CB₁ receptor-mediated mechanism. CB₁ receptor selective antagonists block the increase in feeding associated with administration of anandamide (C. M. Williams, T. C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317; C. C. Felder, E. M. Briley, J. Axelrod, J. T. Simpson, K. Mackie, W. A. Devane, Proc. Natl. Acad. Sci. U.S. A. 90 (16) (1993) 7656-60) and caused appetite suppression and weight loss (G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, G. L. Gessa, Life Sci. 63 (8) (1998) L113-PL117).

[0006] Leptin is the primary signal through which the hypothalamus senses nutritional state and modulates food intake and energy balance. Following temporary food restriction, CB1 receptor knockout mice eat less than their wild-type littermates, and the CB1 antagonist SR141716A reduces food intake in wild-type but not knockout mice. Furthermore, defective leptin signaling is associated with elevated hypothalamic, but not cerebellar, levels of endocannabinoids in obese db/db and ob/ob mice and Zucker rats. Acute leptin treatment of normal rats and ob/ob mice reduces anandamide and 2-arachidonoyl glycerol in the hypothalamus. These findings indicate that endocannabinoids in the hypothalamus may tonically activate CB1 receptors to maintain food intake and form part of the neural circuitry regulated by leptin (V. Di Marzo, S. K. Goparaju, L. Wang, J. Liu, S. Bitkai, Z. Jarai, F. Fezza, G. I. Miura, R. D. Palmiter, T. Sugiura, G. Kunos, Nature 410 (6830) 822-825).

[0007] SR-141716A, a CB1 selective antagonist/inverse agonist is undergoing currently phase III clinical trials for the treatment of obesity. In a double blind placebo-controlled study, at the doses of 5, 10 and 20 mg daily, SR 141716 significantly reduced body weight when compared to placebo (F. Barth, M. Rinaldi-Carmona, M. Arnone, H. Heshmati, G. Le Fur, “Cannabinoid antagonists: From research tools to potential new drugs.” Abstracts of Papers, 222nd ACS National Meeting, Chicago, Ill., United States, Aug. 26-30, 2001).

[0008] Other compounds which have been proposed as CB1 receptor antagonists respectively inverse agonists are aminoalkylindols (AAI; M. Pacheco, S. R. Childers, R. Arnold, F. Casiano, S. J. Ward, J. Pharmacol. Exp. Ther. 257 (1) (1991) 170-183), like 6-bromo-(WIN54661; F. M. Casiano, R. Arnold, D. Haycock, J. Kuster, S. J. Ward, NIDA Res. Monogr. 105 (1991) 295-6) or 6-iodopravadoline (AM630, K. Hosohata, R. M. Quock, R. M; Hosohata, T. H. Burkey, A. Makriyannis, P. Consroe, W. R. Roeske, H. I. Yamamura, Life Sci. 61 (1997) 115-118; R. Pertwee, G. Griffin, S. Fernando, X. Li, A. Hill, A. Makriyannis, Life Sci. 56 (23-24) (1995) 1949-55). Arylbenzo[b]thiophene and benzo[b]furan (LY320135, C. C. Felder, K. E. Joyce, E. M. Briley, M. Glass, K. P. Mackie, K. J. Fahey, G. J. Cullinan, D. C. Hunden, D. W. Johnson, M. O. Chaney, G. A. Koppel, M. Brownstein, J. Pharmacol. Exp. Ther. 284 (1) (1998) 291-7) disclosed in WO9602248, U.S. Pat. No. 5,596,106, 3-alkyl-(5,5-diphenyl)imidazolidinediones (M. Kanyonyo, S. J. Govaerts, E. Hermans, J. H. Poupaert, D. M. Lambert, Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236.) as well as 3-alkyl-5-arylimidazolidinediones (F. Ooms, J. Wouters, O. Oscaro. T. Happaerts, G. Bouchard, P.-A. Carrupt, B. Testa, D. M. Lambert, J. Med. Chem. 45 (9) (2002) 1748-1756) are known to antagonize the CB₁ receptor respectively act as an inverse agonist on the hCB₁ receptor. WO0015609 (FR2783246-A1), WO0164634 (FR2805817-A1), WO0228346, WO0164632 (FR2805818-A1), WO0164633 (FR2805810-A1) disclosed substituted 1-bis(aryl)methyl-azetidines derivatives as antagonists of CB₁. In WO0170700 4,5-dihydro-1H-pyrazole derivatives are described as CB, antagonists. In several patents bridged and non-bridged 1,5-diphenyl-3-pyrazolecarboxamide derivatives are disclosed as CB, antagonists/inverse agonists (WO0132663, WO0046209, WO9719063, EP658546, EP656354, U.S. Pat. No. 5,624,941, EP576357, U.S. Pat. No. 3,940,418).

SUMMARY OF THE INVENTION

[0009] The present invention relates to compounds of formula (I):

[0010] wherein

[0011] R¹, R², R³, R⁴, R⁵, R⁶ and R⁷ are as herein defined, or a pharmaceutically acceptable salt thereof.

[0012] According to one aspect of the present invention, compounds of formula (I) may be selective, directly acting CB1 receptor antagonists respectively inverse agonists. Such antagonists/inverse antagonists are useful in medical therapy, particularly in the treatment and/or prevention of diseases which are associated with the modulation of CB1 receptors.

[0013] Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

[0014] In this specification the term “lower” is used to mean a group consisting of one to eight, preferably of one to four carbon atom(s).

[0015] The term “halogen” refers to fluorine, chlorine, bromine and iodine, preferably to chlorine and fluorine.

[0016] The term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms.

[0017] The term “lower alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to eight carbon atoms, preferably one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n-hexyl, 2-ethylbutyl and the like.

[0018] The term “alkoxy” refers to the group R′—O—, wherein R′ is alkyl. The term “lower alkoxy” refers to the group R′—O—, wherein R′ is lower alkyl. Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy, with methoxy being especially preferred.

[0019] The term “lower alkenyl” refers to a lower alkyl group containing one or more double bond(s) in the alkylene chain. This term is further exemplified by radicals such as vinyl, 1-propenyl, allyl, 1-butenyl, 2-butenyl and 3-butenyl, with allyl being preferred.

[0020] The term “lower alkylamino” refers to the group R′—NH—, wherein R′ is lower alkyl.

[0021] The term “lower alkoxycarbonyl” refers to the group R′-O—C(O)—, wherein R′ is lower alkyl.

[0022] The term “lower alkoxycarbonylamino” refers to the group R′—O—C(O)NH—, wherein R′ is lower alkyl.

[0023] The term “halogenated lower alkyl” refers to a lower alkyl group wherein at least one of the hydrogens of the lower alkyl group is replaced by a halogen atom, preferably fluoro or chloro. Among the preferred halogenated lower alkyl groups are trifluoromethyl, difluoromethyl, fluoromethyl and chloromethyl, with trifluoromethyl being especially preferred. The term “fluorinated lower alkyl” refers to a lower alkyl group wherein at least one of the hydrogens of the lower alkyl group is replaced by fluoro. Among the preferred fluorinated lower alkyl groups are trifluoromethyl, difluoromethyl and fluoromethyl, with trifluoromethyl being especially preferred.

[0024] The term “halogenated lower alkoxy” refers to a lower alkoxy group wherein at least one of the hydrogens of the lower alkoxy group is replaced by halogen, preferably by fluorine or chlorine. Among the preferred halogenated lower alkoxy groups are fluorinated lower alkoxy groups such as trifluoromethoxy, difluoromethoxy and fluoromethoxy, with trifluoromethoxy being especially preferred. The term “fluorinated lower alkoxy” refers to a lower alkoxy group wherein at least one of the hydrogens of the lower alkoxy group is replaced by fluoro. Among the preferred fluorinated lower alkoxy groups are trifluoromethoxy, difluoromethoxy and fluoromethoxy, with trifluoromethoxy being especially preferred.

[0025] The term “di-phenyl-lower alkyl” refers to a lower alkyl group wherein two of the hydrogens of the lower alkyl group is replaced by phenyl. The phenyl moiety may optionally be mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy or halogen.

[0026] The term “phenoxy-lower alkyl” refers to a lower alkyl group wherein one of the hydrogens of the lower alkyl group is replaced by phenoxy. The phenyl moiety of the phenoxy-lower alkyl residues may optionally be mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy or halogen.

[0027] The term “cycloalkyl” refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0028] The term “cycloalkenyl” refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms, which carbocyclic ring contains at least on double bond. This term is further exemplified by radicals such as cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl being preferred.

[0029] The term “pharmaceutically acceptable salts” embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.

DETAILED DESCRIPTION OF THE INVENTION

[0030] In particular, the present invention relates to compounds of formula (I):

[0031] wherein

[0032] R¹ is hydrogen, or lower alkyl;

[0033] R² is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a);

[0034] or R¹ and R² together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing one or two further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy;

[0035] R^(2a) is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

[0036] R³ is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH₂)_(n)—R^(3a);

[0037] R^(3a) is cycloalkyl fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

[0038] R⁴ is lower alkyl, lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH₂)_(p)—O— or —(CH₂)₂—O—;

[0039] R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl;

[0040] R⁷ is hydrogen, lower alkyl or halogen;

[0041] m is 0, 1, 2 or 3;

[0042] n is 0, 1, 2, 3 or 4;

[0043] p is 1, 2 or 3;

[0044] or a pharmaceutically acceptable salts thereof.

[0045] In one embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R¹ is hydrogen or lower alkyl.

[0046] Preferable lower alkyl residues R¹ are methyl and ethyl, with methyl being especially preferred. Most preferably, R¹ is hydrogen.

[0047] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R² is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a).

[0048] Preferable lower alkyl residues R² are branched or straight chain alkyl residues with one to eight, preferably three to five carbon atoms, such as n-propyl, n-butyl, s-butyl, isobutyl, n-pentyl and 2-ethylhexyl. Most preferred lower alkyl residues R² are n-propyl, n-butyl, s-butyl, isobutyl and n-pentyl. Preferable lower alkenyl residues R² are 1-butenyl and allyl, with allyl being especially preferred. Preferable lower alkoxy-lower alkyl residues R² are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl and ethoxypropyl, with methoxyethyl and methoxypropyl being especially preferred. Preferable lower alkoxycarbonylamino groups R² are methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino and butoxycarbonylamino, with ethoxycarbonylamino being especially preferred. Preferable residues R² are lower alkyl as defined above, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a), wherein R^(2a) is as defined below and m is 0 or 1, preferably 0. Most preferable residues R² are lower alkyl as defined above or —(CH₂)_(m)—R^(2a), wherein R^(2a) is as defined below and m is 0 or 1, preferably 0.

[0049] In one embodiment, R^(2a) is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro.

[0050] Preferable cycloalkyl residues R^(2a) are cycloalkyl residues with three to six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, which may optionally be mono-, di-, tri-or tetra-substituted, preferably mono-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, preferably by lower alkyl, such as methyl, and/or hydroxy. Most preferable cycloalkyl residues R^(2a) are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 2-hydroxycyclopentyl.

[0051] Preferable cycloalkenyl residues R^(2a) are cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl, preferably cyclohex-1-enyl, being especially preferred. Preferable heterocyclic rings R^(2a) are 5-or 6-memberd, with 5-membered being especially preferred, and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Preferably, heterocyclic rings R^(2a) are unsubstituted. Most preferred heterocyclic rings R^(2a) are piperidinyl, morpholino and tetrahydrofuranyl, with piperidinyl and morpholino being especially preferred. Preferable heteroaromatic rings R^(2a) are 5-or 6-membered and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R^(2a) are pyridinyl, pyrimidinyl, thiazolyl and isoxazolyl, optionally substituted as defined above. Preferably, heteroaromatic rings R^(2a) are unsubstituted or mono-substituted by lower alkyl, preferably methyl. Most preferable heteroaromatic rings R^(2a) are pyridinyl, pyrimidinyl, 4-methylthiazolyl or 5-methylisoxazolyl. Preferable phenyl residues R^(2a) are optionally mono-, di- or tri-substituted, preferably mono-or di-substituted, independently, by lower alkoxy, such as methoxy, halogen, such as chloro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy, or nitro. Most preferable phenyl residues R^(2a) are unsubstituted phenyl, 4-trifluoromethyl-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3,4-dimethoxy-phenyl, 2-nitro-phenyl and 4-trifluoromethoxy-phenyl. Preferably, m is 0, 1 or 2, more preferably m is 0 or 1, most preferably m is 0.

[0052] In another embodiment, R¹ and R² together with the nitrogen atom to which they are attached form a 5- or 6-membered, saturated heterocyclic ring optionally containing one or two, preferably one, further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, preferably oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Preferably, heterocyclic rings formed by R¹ and R² together with the nitrogen atom to which they are attached are unsubstituted, with unsubstituted pyrrolidinyl, piperidinyl and morpholino being especially preferred.

[0053] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R³ is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH₂)_(n)—R^(3a).

[0054] Preferable lower alkyl residues R³ are branched or straight chain alkyl residues with one to six, preferably four carbon atoms, such as ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, n-pentyl and n-hexyl. Most preferred lower alkyl residues R³ are n-butyl and s-butyl. Preferable lower alkenyl residues R³ are 1-butenyl and allyl, with allyl being especially preferred. Preferable lower alkoxy-lower alkyl residues R³ are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl and ethoxypropyl, with methoxyethyl and methoxypropyl being especially preferred. Preferable di-phenyl-lower alkyl is di-phenyl-methyl. Most preferably, R³ is a residue —(CH₂)_(n)—R^(3a), wherein R is as defined below and n is 1 or 2, preferably 1.

[0055] In one embodiment, R^(3a) is cycloalkyl fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro.

[0056] Preferable cycloalkyl residues R^(3a) are cycloalkyl residues with five or six carbon atoms, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, or which may optionally be fused to a phenyl ring. Preferably, cycloalkyl residues R^(3a) are unsubstituted, such as unsubstituted cyclopentyl or unsubstituted cyclohexyl, with unsubstituted cyclohexyl being preferred, or fused to a phenyl residue, such as indanyl. Preferable cycloalkenyl residues R^(2a) are cyclobutenyl, cyclopentenyl and cyclohexenyl, with cyclohexenyl, preferably cyclohex-1-enyl, being especially preferred. Preferable heterocyclic rings R^(3a) are 5-or 6-memberd and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy. Examples of heterocyclic rings R^(3a) are piperidinyl, morpholino and pyrrolidinyl, optionally substituted as defined above. Preferably, heterocyclic rings R^(3a) are unsubstituted or substituted by lower alkyl, such as methyl or ethyl, with ethyl being especially preferred. Most preferred heterocyclic rings R^(3a) are piperidinyl, morpholino and 1-ethyl-pyrrolidinyl. Preferable heteroaromatic rings R^(3a) are 5-or 6-membered and contain one to three, preferably one, heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R^(3a) are furyl, thienyl and pyridinyl, optionally substituted as defined above. Preferably, heteroaromatic rings R^(3a) are unsubstituted or mono-substituted by lower alkyl, preferably methyl. Most preferable heteroaromatic rings R^(3a) are furyl, thienyl, 3-methylthienyl and pyridinyl. Preferable phenyl residues R^(3a) are optionally mono-, di- or tri-substituted, preferably mono-or di-substituted, most preferably mono-substituted, independently, by hydroxy, lower alkyl, such as methyl or isopropyl, lower alkoxy, such as methoxy, halogen, such as chloro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy, or nitro. Most preferable phenyl residues R^(3a) are unsubstituted phenyl, 2-methyl-phenyl, 4-methyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 4-isopropyl-phenyl, 4-chloro-phenyl, 3,4-dichloro-phenyl, 3,5-dichloro-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 2,4-dimethoxy-phenyl, 3,4,5-trimethoxy-phenyl, 3-trifluoromethoxy-phenyl, 4-trifluoromethoxy-phenyl, 3-trifluormethyl-4-chlorophenyl and 4-nitro-phenyl, with 4-methoxy-phenyl being especially preferred. Most preferable residue R^(3a) is a phenyl residue as defined above.

[0057] Preferably, n is 0, 1, 2 or 3, more preferably n is 1 or 2, most preferably n is 1.

[0058] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R⁴ is lower alkyl; lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH₂)_(p)—O— or —(CH₂)₂—O—.

[0059] Preferable lower alkyl residues R⁴ are branched or straight chain alkyl residues with one to six, preferably one to three carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl, isobutyl and n-pentyl. Most preferred lower alkyl residue R⁴ is methyl. Preferable lower alkoxycarbonylamino groups R⁴ are methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino and butoxycarbonylamino, with ethoxycarbonylamino being especially preferred. Preferable cycloalkyl residues R⁴ are cycloalkyl residues with three to six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, which may optionally be mono-, di-, tri-or tetra-substituted, preferably mono-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy, preferably by lower alkyl, such as methyl, and/or hydroxy. Most preferable cycloalkyl residue R⁴ is unsubstituted cyclohexyl. Preferable heteroaromatic rings R⁴ are 5-or 6-membered and contain one to three, preferably one or two, heteroatoms independently selected from nitrogen, oxygen and sulfur, preferably selected form nitrogen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino. Examples of heteroaromatic rings R⁴ are pyridinyl, pyrazinyl and thiazolyl, optionally substituted as defined above. Preferably, heteroaromatic rings R⁴ are unsubstituted or mono-substituted by lower alkyl, such as methyl and ethyl, or by lower alkoxy, such as methoxy. Most preferable heteroaromatic rings R⁴ are 2-methoxy-pyridinyl, 2-methyl-pyridinyl, pyrazinyl and 2-methyl-thiazolyl.

[0060] Preferable phenoxy-lower alkyl residues R⁴ are phenoxy-methyl and phenoxy ethyl, wherein the phenyl moiety may optionally be mono-substituted by lower alkoxy, such as methoxy. Most preferable phenoxy-lower alkyl residue R⁴ is 3-methoxy-phenoxy-methyl.

[0061] Preferable phenyl residues R⁴ are mono-, di- or tri-substituted, preferably mono-or di-substituted, most preferably mono-substituted, independently, by hydroxy, lower alkyl, such as methyl, ethyl or t-butyl, lower alkoxy, such as methoxy, halogen, such as chloro or fluoro, halogenated lower alkyl, such as trifluoromethyl, halogenated lower alkoxy, such as trifluoromethoxy or nitro. Alternatively, two adjacent substituents of the said phenyl residue together may be —O—(CH₂)_(p)—O— or —(CH₂)₂—O—, wherein p is 1, 2 or 3, preferably 1 or 2, most preferably 1. Preferable substituents of phenyl residues R⁴ are nitro and lower alkoxy, or two adjacent substituents being —O—CH₂—O—. Most preferable substituted phenyl residues R⁴ are 2-methyl-phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-t-butyl-phenyl, 2-chloro-phenyl, 4-chloro-phenyl, 2,4-dichloro-phenyl, 2-fluoro-phenyl, 4-fluoro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, 3,5-dimethoxy-phenyl, 4-hydroxy-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-nitro-phenyl, benzo[1,3]dioxolyl and 2,3-dihydro-benzofuranyl, with 4-methoxyphenyl, 4-nitro-phenyl and benzo[1,3]dioxolyl being especially preferred.

[0062] Preferable residues R⁴ are cycloalkyl residues and substituted phenyl residues as defined above.

[0063] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl.

[0064] Preferable lower alkyl residues R⁵ and R⁶ are methyl and ethyl, with methyl being especially preferred. Preferable halogen residues R⁵ and R⁶ are fluoro and chloro, with chloro being especially preferred. Preferable residue R⁵ is lower alkyl, such as methyl. Preferable residues R⁶ are hydrogen and lower alkyl, such as methyl.

[0065] In another embodiment, the present invention relates to a compound of formula (I) as defined above, wherein R⁷ is hydrogen, lower alkyl or halogen.

[0066] Preferable lower alkyl residues R⁷ are methyl and ethyl, with methyl being especially preferred. Preferable halogen residues R⁷ are fluoro and chloro, with chloro being especially preferred. Preferable residue R⁷ are hydrogen and lower alkyl, such as methyl.

[0067] Preferred compounds of general formula (I) are the compounds of Examples 1 to 377, preferably 1 to 375 (see section Examples below) and pharmaceutically acceptable salts thereof.

[0068] Especially preferred are the compounds selected from the group consisting of:

[0069] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid butylamide,

[0070] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid butylamide,

[0071] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid sec-butylamide,

[0072] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrr ole-3-carboxylic acid sec-butylamide,

[0073] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide,

[0074] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide,

[0075] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid isobutyl-amide,

[0076] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid allylamide,

[0077] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid cyclohexylmethyl-amide,

[0078] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxy lic acid cyclohexylmethyl-amide,

[0079] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid cyclohexylmethyl-amide,

[0080] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-py rrole-3-carboxylic acid cyclohexylmethyl-amide,

[0081] 4-[1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic acid ethyl ester,

[0082] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,

[0083] N′-{1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carbonyl}-hydrazinecarboxylic acid ethyl ester,

[0084] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,

[0085] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone,

[0086] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid phenylamide,

[0087] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pyrimidin-2-ylamide,

[0088] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (5-hydroxy-2,2,6-trimethyl-cyclohexylmethyl)-amide,

[0089] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic acid butylamide,

[0090] Benzyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0091] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-pyrrolidin-1-yl-methanone,

[0092] Cyclohexylmethyl-5-[2-(3,4-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0093] Cyclohexylmethyl-5-[2-(3-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0094] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0095] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0096] Cyclohexylmethyl-5-[2-(2-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0097] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0098] Cyclohexylmethyl-5-[2-(3,5-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0099] Cyclohexylmethyl-2-methyl-5-(2-m-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0100] Cyclohexylmethyl-2-methyl-5-(2′-methyl-[2,4′]bithiazolyl-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0101] Cyclohexylmethyl-5-[2-(4-ethyl-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0102] 5-[2-(4-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0103] 5-[2-(4-tert-Butyl-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0104] Cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0105] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0106] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0107] Cyclohexylmethyl-5-[2-(2,4-dichloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0108] Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0109] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pentylamide,

[0110] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid propylamide,

[0111] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,

[0112] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide,

[0113] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide,

[0114] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide,

[0115] (trans) rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-cyclopentyl)-amide,

[0116] 1-(4-Chloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0117] 1-(3,4-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0118] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0119] 1-(3,4-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0120] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0121] 1-(4-Isopropyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0122] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid butylamide,

[0123] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0124] and pharmaceutically acceptable salts thereof.

[0125] Most preferred compounds of general formula (I) are those selected from the group consisting of:

[0126] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid butylamide,

[0127] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,

[0128] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone,

[0129] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0130] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0131] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide,

[0132] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0133] Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide,

[0134] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pentylamide,

[0135] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,

[0136] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide,

[0137] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide,

[0138] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0139] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,

[0140] or a pharmaceutically acceptable salt thereof.

[0141] The present invention also relates to a process for the manufacture of compounds of formula (I) as defined above. The compounds of formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below or in the Examples or by methods known in the art.

[0142] The compounds of formula (I) may be prepared using the general methods described below:

[0143] Compounds of formula (I), wherein R¹ to R⁷ and m are as previously defined, can be prepared by reaction of enamines of formula A with alfa-bromoketones of formula B according to methods known in the art (Scheme 1). For example, the reaction can be performed in an inert solvent such as DMF in the presence of a hindered base such as 2,6-di-tert-butylpyridine or 2,6-lutidine.

[0144] Compounds of formula I can be purified by methods known in the art such as precipitation from mixtures of solvents (e.g. acetonitrile and water) or by column chromatography using SiO₂ with eluents know in the art (e.g. n-heptane/Ethyl acetate, dichloromethane/methanol and dichloromethane/(1% NH₃ in MeOH)).

[0145] Thiazole derivatives of formula B can be prepared from dibromodiketones of formula C and thioamides of formula C by methods known in the art (Scheme 2). For example, the reaction can be performed by addition of thioamides of formula C to dibromo-diketones of formula D in an inert solvent such as DMF.

[0146] Enamines of formula A can be prepared from beta-ketoamides of formula E and amines of formula F by methods known in the art (Scheme 3). For example a beta-keto amide of formula E can be reacted with an amine of formula B in a suitable inert solvent (e.g. DMF) in the presence of a hindered base (e.g. 2,6-di-tert-butylpyridine) to yield enamine of formula A.

[0147] Beta-ketoamides of formula E are either known form the literature or can be purchased from commercial sources or else can be prepared by methods known in the art. For example, beta-ketoamides of formula E wherein R⁵═methyl can be prepared by reaction of amines of formula G with diketene in an inert solvent such as dichloromethane (Scheme 4).

[0148] Compounds of formula D, F and G are either known from the literature or can be purchased from commercial sources or else can be synthesized by methods known in the art.

[0149] The invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.

[0150] Some compounds of formula (I) may possess asymmetric centres and are therefore capable of existing in more than one stereoisomeric form. The invention thus also relates to compounds in substantially pure isomeric form at one or more asymmetric centres as well as mixtures, including racemic mixtures, thereof. Such isomers may be prepared by asymmetric synthesis, for example using chiral intermediate, or mixtures may be resolved by conventional mehtods, eg., chromatography (chromatography with a chiral adsorbens or eluent), or use of a solving agent.

[0151] It will be appreciated, that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.

[0152] As described above, the compounds of formula (I) or pharmaceutically acceptable salts thereof can be used as medicaments for the treatment and/or prophylaxis of diseases which are associated with the modulation of the CB1 receptors.

[0153] The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

[0154] Further, the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

[0155] In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, which method comprises administering a compound as defined above to a human being or animal.

[0156] The invention further relates to the use of compounds as defined above for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

[0157] In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors. Such medicaments comprise a compound as defined above.

[0158] In this context, the expression ‘diseases associated with modulation of CB1 receptors’ means diseases which can be treated and/or prevented by modulation of CB1 receptors. Such diseases encompass, but are not limited to, psychic disorders, especially anxiety, psychosis, schizophrenia, depression, abuse of psychotropes, for example for the abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency, neuropathies, migraine, stress, epilepsy, dyskinesias, Parkinson's disease, amnesia, cognitive disorders, senile dementia, Alzheimer's disease, eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), gastrointestinal diseases, vomiting, diarrhea, urinary disorders, cardiovascular disorders, infertility disorders, inflammations, infections, cancer, neuroinflammation, in particular in atherosclerosis, or the Guillain-Barré syndrome, viral encephalitis, cerebral vascular incidents and cranial trauma.

[0159] In a preferable aspect, the expression ‘diseases associated with modulation of CB1 receptors’ relates to eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency. In a more preferable aspect, the said term related to eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), abuse and/or dependence of a substances, including alcohole dependency and nicotine dependency, with obesity being especially preferred.

[0160] It is a further preferred object to provide a method of treatment or prevention of Type II diabetes (non-insulin dependent diabetes mellitus (NIDDM) in a human which comprises administration of a therapeutically effective amount of a compound according to formula (I) in combination or association with a therapeutically effective amount of a lipase inhibitor, particularly, wherein the lipase inhibitor is orlistat. Also an object of the invention is the method as described above for the simultaneous, separate or sequential administration of a compound according to formula (I) and a lipase inhibitor, particularly tetrahydrolipstatin.

[0161] It is a further preferred object to provide a method for the treatment or prevention of obesity and obesity related disorders which comprises administration of a therapeutically effective amount of a compound according to formula (I) in combination or association with a therapeutically effective amount of other drugs for the treatment of obesity or eating disorders so that together they give effective relief. Suitable other drugs include but are not limited to anorectic agents, lipase inhibitors and selective serotonin reuptake inhibitors (SSRI). Combinations or associations of the above agents may be encompassing separate, sequential or simultaneous administration.

[0162] Preferable lipase inhibitor is tetrahydrolipstatin.

[0163] Suitable anorectic agents of use in combination with a compound of the present invention include, but are not limited to, aminorex, amphechloral, amphetamine, benzphetamine, chlorphentermine, clobenzorex, cloforex, clominorex, clortermine, cyclexedrine, dexfenfluramine, dextroamphetamine, diethylpropion, diphemethoxidine, N-ethylamphetamine, fenbutrazate, fenfluramine, fenisorex, fenproporex, fludorex, fluminorex, furfurylmethylamphetamine, levamfetamine, levophacetoperane, mazindol, mefenorex, metamfepramone, methamphetamine, norpseudoephedrine, pentorex, phendimetrazine, phenmetrazine, phentermine, phenylpropanolamine, picilorex and sibutramine, and pharmaceutically acceptable salts thereof.

[0164] Most preferable anorectic agents are sibutramine and phentermine.

[0165] Suitable selective serotonin reuptake inhibitors of use in combination with a compound of the present invention include: fluoxetine, fluvoxamine, paroxetine and sertraline, and pharmaceutically acceptable salts thereof.

[0166] Demonstration of additional biological activities of the compounds of the present invention may be accomplished through in vitro, ex vivo, and in vivo assays that are well known in the art. For example, to demonstrate the efficacy of a pharmaceutical agent for the treatment of obesity-related disorders such as diabetes, Syndrome X, or atherosclerotic disease and related disorders such as hypertriglyceridemia and hypercholesteremia, the following assays may be used.

[0167] Method for Measuring Blood Glucose Levels

[0168] db/db mice (obtained from Jackson Laboratories, Bar Harbor, Me.) are bled (by either eye or tail vein) and grouped according to equivalent mean blood glucose levels. They are dosed orally (by gavage in a pharmaceutically acceptable vehicle) with the test compound once daily for 7 to 14 days. At this point, the animals are bled again by eye or tail vein and blood glucose levels are determined.

[0169] Method for Measuring Triglyceride Levels

[0170] hApoAl mice (obtained from Jackson Laboratories, Bar Harbor, Me.) are bled (by either eye or tail vein) and grouped according to equivalent mean serum triglyceride levels. They are dosed orally (by gavage in a pharmaceutically acceptable vehicle) with the test compound once daily for 7 to 14 days. The animals are then bled again by eye or tail vein, and serum triglyceride levels are determined. Method for Measuring HDL-Cholesterol Levels

[0171] To determine plasma HDL-cholesterol levels, hApoAl mice are bled and grouped with equivalent mean plasma HDL-cholesterol levels. The mice are orally dosed once daily with vehicle or test compound for 7 to 14 days, and then bled on the following day. Plasma is analyzed for HDL-cholesterol.

[0172] In addition, to demonstrate CNS activities of the compounds of the present invention, the following in vivo assays may be used.

[0173] Method for Testing Task Learning and Spatial Memory

[0174] The Morris Water Maze is routinely used to assess task learning and spatial memory (Jaspers et al., Neurosci. Lett. 117:149-153, 1990; Morris, J. Neurosci. Methods 11:47-60, 1984). In this assay, animals are placed in a water pool which is divided into quadrants. One platform is hidden in one of the quadrants. The animal is placed in the water pool and is expected to locate the hidden platform within a predetermined time. During a number of training trials, the animal learns the location of the platform and escape from the pool. The animal receives multiple trials in this task. Total distance traveled, number of trials to locate platform, latency to find platform, and the swimming path is recorded for each animal. The animal's learning ability is measured by the length of time or number of trials required to find the hidden platform. Memory deficit or improvement is determined by the number of trials or the latency to find the platform at predetermined delay time after acquisition. Leaning and memory may be measured by the number of times that the animal crosses the quadrant where the platform was located during the acquisition phase.

[0175] Method for Testing Drug Dependence

[0176] Self-administration in animals is a predictor of a compound's abuse potential in humans. Modifications to this procedure may also be used to identify compounds that prevent or block the reinforcing properties of drugs that have abuse potential. A compound that extinguishes the self-administration of a drug may prevent that drug's abuse or its dependence. (Ranaldi et al., Psychopharmacol. 161:442-448, 2002; Campbell et al., Exp. Clin. Psychopharmacol. 8:312-25, 2000). In a self-administration test, animals are placed in the operant chambers containing both an active and inactive lever. Each response on the active lever produces an infusion of either the test compound or a drug known to be self-administered. Presses on the inactive lever have no effect, but are also recorded. Animals are then trained to self-administer compound/drug over a set period of time by having drug access during each daily session. Illumination of the chamber house light signals the beginning of the session and the availability of the compound/drug. When the session ends, the house light is turned off. Initially, a drug infusion occurs with every press of the active lever. Once lever-pressing behavior has been established, the number of presses to produce a drug infusion is increased. After stable compound/drug self-administration is obtained, the effect of a second compound on the drug-reinforced behavior may be evaluated. Administration of this second compound prior to the session can either potentiate, extinguish, or produce no change to the self-administrating behavior.

[0177] The following tests were carried out in order to determine the activity of the compounds of formula (I).

[0178] The affinity of the compounds of the invention for cannabinoid CB1 receptors was determined using membrane preparations of human embryonic kidney (HEK) cells in which the human cannabis CB1 receptor is transiently transfected using the Semliki Forest Virus system in conjunction with [3H]-CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.

[0179] The affinity of the compounds of the invention for cannabinoid CB2 receptors was determined using membrane preparations of human embryonic kidney (HEK) cells in which the human cannabis CB2 receptor is transiently transfected using the Semliki Forest virus system in conjunction with [3H]-CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.

[0180] The cannabinoid CB1 antagonistic activity of compounds of the invention was determined by functional studies using CHO cells in which human cannabinoid CB1 receptors are stably expressed (see M. Rinaldi-Carmona et. al., J. Pharmacol. Exp. Ther. 278 (1996) 871).

[0181] The stable expression of the human cannabinoid receptor in cell systems was first described in Nature 1990, 346, 561-564 (CB1) and Nature 1993, 365, 61-65 (CB2) respectively. Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB1 receptors by CB1 receptor agonist (e.g., CP-55,940 or (R)-WIN-55212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration dependent manner. This CB1 receptor mediated response can be antagonised by CB1 receptor antagonists such as the compounds of the invention,

[0182] The compounds of formula (I) show an excellent affinity for the CB1 receptor, determined with the experimental conditions described in Devane et.al. Mol. Pharmacol. 34 (1988) 605-613. The compounds of the present invention or the pharmaceutically acceptable salts or sovants are antagonists and selective for the CB1 receptor with affinites below IC₅₀=2 μM. They exhibit at least a 10 fold selectivity against the CB2 receptor. Compound of Example IC₅₀ [μM] 8 <2 299 <2 305 <2 311 <2 315 <2 324 <2 333 <2 340 <2 356 <2 371 <2 375 <2

[0183] Effect of CB1 Receptor Antagonist/Inverse Agonist on CP 55,940-induced Hypothermia in NMRI Mice

[0184] Animals

[0185] Male NMRI mice were used in this study and were obtained from Research Consulting Company Ltd (RCC) of Fillinsdorf (Switzerland). Mice, weighing 30-31 g were used in this study. Ambient temperature is approximately 20-21° C. and relative humidity 55-65%. A 12 hours light-dark cycle is maintained in the rooms with all tests being performed during the light phase. Access to tap water and food are ad libitum.

[0186] Method

[0187] All measurements were made between 12:00 am and 5:00 pm. Mice were brought in this environment and habituated for at least two hours before the start of the experiment. They had always free access to food and water. For each dose, 8 mice were used. Rectal body temperature measurements were recorded by mean of a rectal probe (RET2 of Physitemp) and digital thermometer (Digi-sense n°8528-20 of Cole Parmer, Chicago USA). The probe was inserted about 3.5 cm in each mouse.

[0188] The body temperature was taken 15 min before administration of either Vehicle or CB1 receptor antagonist/inverse agonist. 30 or 90 min after i.p. or p.o. administration of this compound, respectively, rectal body temperature was recorded in order to evaluate any influence of the compound itself. The CB receptor agonist CP 55,940 (0.3 mg/kg) was immediately administered intravenously, then 20 min after i.v. administration of CP 55940, body temperature was again measured.

[0189] The In Vivo Activity of Compounds of Formula (1) was Assessed for their Ability to Regulate Feeding Behaviour by Recording Food Consumption in Food Deprived Animals.

[0190] Rats were trained to have access to food for 2 h per day and were food deprived for 22 h. When they were trained under this schedule, the amount of food taken every day during these 2 h food intake session was consistent day after day.

[0191] To test the ability of compounds of formula (1) to decrease food intake, 8 animals were used in a cross-over study. Rats were individually housed in Plexiglas boxes with a grid on the floor and a paper was placed below the cage floor to collect any spillage. A food dispenser (becher) filled with a pre-weighed amount of food was presented to them for 2 h. At the end of the food intake session, rats returned to their home cage. Each rat was weighed before the start of the experiment and the amount of food consumed during this 2 h food intake session was recorded. Either various doses of test compound or vehicle was administered orally 60 min before the 2 h food intake session. A positive control Rimonabant (SR141716) was included in the experiment. An Anova analysis with repeated measures was used followed by a posthoc test Student Neumann-Keuls. *P<0.05 compared to Saline-treated rats.

[0192] Furthermore the utility of compounds of formula (1) in diseases or disorders may be demonstrated in animal disease models that have been reported in the literature. The following are examples of such animal disease models: a) reduction of sweet food intake in marmosets (Behavioural Pharm, 1998, 9,179-181); b) reduction of sucrose and ethanol intake in mice (Psychopharm. 1997, 132, 104-106); c) increased motor activity and place conditioning in rats (Psychopharm. 1998, 135, 324-332; Psychopharmacol 2000, 151: 25-30); d) spontaneous locomotor activity in mice (J. Pharm. Exp. Ther. 1996, 277, 586-594); e) reduction in opiate self-administration in mice (Sci. 1999, 283, 401-404);

[0193] The compounds of formula (I) and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.

[0194] The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula (I) and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

[0195] Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).

[0196] Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

[0197] Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

[0198] The dosage of the compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.

[0199] The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula (I).

[0200] The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

EXAMPLES

[0201] MS=mass spectrometry; ISP=ion spray (positive ion), corresponds to ESI and ES+ (electrospray, positive ion); mp=melting point.

Example 1 Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0202]

[0203] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-nitrophenyl thioamide as R⁴C(S)NH₂, as follows:

[0204] Synthesis of 2-bromo-1-[2-(4-nitro-phenyl)-thiazol-4-yl]-ethanone (Compound B)

[0205] To a solution of 1.4 g of 1,4-dibromo-2,3-butanedione in dimethylformamide (110 ml) at room temperature was added 1.4 ml of 2,6-di-tert-butylpyridine. Then a solution of 1.0 g of 4-nitro-phenyl-thiobenzamide in 20 ml of dimethylformamide was slowly added to the reaction mixture over 1 hour. The reaction mixture was then allowed to stir for an additional hour at room temperature before being concentrated in vacuo. The residue was then purified by chromatography over a short column (SiO₂, 120 g, CH₂Cl₂ 100%). The isolated compound was triturated with isopropylether to yield 771 mg of the title compound as a yellow solid, mp=186-187° C., MS (EI) 326(M).

[0206] Synthesis of 1-Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0207] To a solution of 4.2 g of diketene in dichloromethane (70 ml) cooled at 0° C. was added over 1 hour a solution of 3.7 g of butylamine in 50 ml of dichloromethane. The reaction mixture was then stirred for one hour at 0° C. and then let to stir at room temperature for another hour. The reaction mixture was then concentrated in vacuo and the crude residue was partitioned in batches which were directly used in the next step.

[0208] To 180 mg of the previous crude material in 5 ml of dimethylformamide was added 0.15 ml of cyclohexylmethylamine together with 0.13 ml of trimethyl orthoformate and the reaction mixture was stirred for 24 hours at room temperature. After such time, 260 mg of 2-bromo-1-[2-(4-nitro-phenyl)-thiazol-4-yl]-ethanone was added together with 0.14 ml of 2,6-lutidine and the reaction mixture was stirred for another 24 hours at room temperature. After such time, 5 ml of a MeCN—H₂O (1:1) solution is added to the reaction mixture, the precipitate is filtrated and washed with MeCN—H₂O (1:1) and isopropylether to yield 264 mg of the title compound as a yellow solid, mp=184-187° C., MS (ISP) 481.3 (M+H)⁺.

[0209] Examples 2-375 were synthesized in analogy to Example 1, using the indicated educts.

Example 2

[0210] Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0211] The title compound was obtained using butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) 430 (M+H)⁺.

Example 3

[0212] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0213] The title compound was obtained using butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 4

[0214] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0215] The title compound was obtained using butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) (M+H)⁺.

Example 5

[0216] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

[0217] The title compound was obtained using butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 6

[0218] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0219] The title compound was obtained using butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 398 (M+H)⁺.

Example 7

[0220] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0221] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 8

[0222] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0223] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thiobenzamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 9

[0224] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0225] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 10

[0226] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

[0227] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridinecarbothioamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 11

[0228] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0229] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 438 (M+H)⁺.

Example 12

[0230] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0231] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chlorophenyl thioamide as R⁴C(S)NH₂, MS(ES+) 458 (M+H)⁺.

Example 13

[0232] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0233] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 14

[0234] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0235] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 484 (M+H)⁺.

Example 15

[0236] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0237] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothioamide as R⁴C(S)NH₂, MS(ES+) 453 (M+H)⁺.

Example 16

[0238] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0239] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothiamide as R⁴C(S)NH₂, MS(ES+) 439 (M+H)⁺.

Example 17

[0240] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0241] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothiamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 18

[0242] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0243] The title compound was obtained using butylamine as R¹R²NH, 2-methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 428 (M+H)⁺.

Example 19

[0244] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0245] The title compound was obtained using butylamine as R¹R²NH, 2-methoxyethylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 400 (M+H)⁺.

Example 20

[0246] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0247] The title compound was obtained using butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chlorophenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 21

[0248] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0249] The title compound was obtained using butylamine as R¹R²NH, 3-(aminomethyl)-thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxy-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 450 (M+H)⁺.

Example 22

[0250] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0251] The title compound was obtained using butylamine as R¹R²NH, 3-furyl methylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothioamide as R⁴C(S)NH₂, MS(ES+) 449 (M+H)⁺.

Example 23

[0252] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0253] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-chlorophenyl thioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 24

[0254] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0255] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 25

[0256] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0257] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 520 (M+H)⁺.

Example 26

[0258] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0259] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 489 (M+H)⁺.

Example 27

[0260] 4-[4-Butylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0261] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 28

[0262] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0263] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 475 (M+H)⁺.

Example 29

[0264] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0265] The title compound was obtained using butylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(n)—NH₂ and pyrazine-2-carbothiamide as R⁴C(S)NH₂, MS(ES+) 462 (M+H)⁺.

Example 30

[0266] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0267] The title compound was obtained using butylamine as R¹R²NH, methoxypropylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 442 (M+H)⁺.

Example 31

[0268] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0269] The title compound was obtained using butylamine as R¹R²NH, methoxypropylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethane thioamide as R⁴C(S)NH₂, MS(ES+) 472 (M+H)⁺.

Example 32

[0270] 4-[4-Butylcarbamoyl-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0271] The title compound was obtained using butylamine as R¹R²NH, methoxypropylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 408 (M+H)⁺.

Example 33

[0272] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0273] The title compound was obtained using butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 34

[0274] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0275] The title compound was obtained using butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 35

[0276] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0277] The title compound was obtained using butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 36

[0278] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0279] The title compound was obtained using butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 37

[0280] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide

[0281] The title compound was obtained using butylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 533 (M+H)⁺.

Example 38

[0282] rac-1-Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0283] The title compound was obtained using sec-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 430 (M+H)⁺.

Example 39

[0284] rac-1-Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0285] The title compound was obtained using sec-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 40

[0286] rac-1-Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0287] The title compound was obtained using sec-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 41

[0288] rac-1-Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0289] The title compound was obtained using sec-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 425 (M+H)⁺.

Example 42

[0290] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0291] The tide compound was obtained using sec-butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 430 (M+H)⁺.

Example 43

[0292] rac-1-Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0293] The title compound was obtained using sec-butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 44

[0294] rac-1-Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0295] The title compound was obtained using sec-butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 45

[0296] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0297] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as. R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 46

[0298] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0299] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 47

[0300] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0301] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 48

[0302] rac-1-Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0303] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 49

[0304] rac-1-Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0305] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 438 (M+H)⁺.

Example 50

[0306] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0307] The title compound was obtained using sec-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 458 (M+H)⁺.

Example 51

[0308] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0309] The title compound was obtained using sec-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 52

[0310] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0311] The title compound was obtained using sec-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 484 (M+H)⁺.

Example 53

[0312] rac-2-Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0313] The title compound was obtained using sec-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 54

[0314] rac 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0315] The title compound was obtained using sec-butylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 428 (M+H)⁺.

Example 55

[0316] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0317] The title compound was obtained using sec-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 56

[0318] rac-1-Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0319] The title compound was obtained using sec-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 450 (M+H)⁺.

Example 57

[0320] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0321] The title compound was obtained using sec-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 449 (M+H)⁺.

Example 58

[0322] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0323] The title compound was obtained using sec-butylamine as R¹R²NH, 4-methoxybenzyl-amine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 59

[0324] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0325] The title compound was obtained using sec-butylamine as R¹R²NH, 4-methoxybenzyl-amine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 60

[0326] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0327] The title compound was obtained using sec-butylamine as R¹R²NH, 4-methoxybenzyl-amine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 520 (M+H)⁺.

Example 61

[0328] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0329] The title compound was obtained using sec-butylamine as R¹R²NH, 4-methoxybenzyl-amine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 489 (M+H)⁺.

Example 62

[0330] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0331] The title compound was obtained using sec-butylamine as R¹R²NH, 4-methoxybenzyl-amine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 462 (M+H)⁺.

Example 63

[0332] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0333] The title compound was obtained using sec-butylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 442 (M+H)⁺.

Example 64

[0334] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0335] The title compound was obtained using sec-butylamine as R¹R²NH, methoxyethylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 472 (M+H)⁺.

Example 65

[0336] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0337] The title compound was obtained using sec-butylamine as R¹R²NH, 3-(aminomethyl)-thiophene as R³— (CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 66

[0338] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0339] The title compound was obtained using sec-butylamine as R¹R²NH, 3-(aminomethyl)-thiophene as R³— (CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 67

[0340] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0341] The title compound was obtained using sec-butylamine as R¹R²NH, 3-(aminomethyl)-thiophene as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 68

[0342] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Sec-butylamide

[0343] The title compound was obtained using sec-butylamine as R¹R²NH, 3-(aminomethyl)-thiophene as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 69

[0344] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide

[0345] The title compound was obtained using sec-butylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 538 (M+H)⁺.

Example 70

[0346] Butyl-5-[2-(2-chloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0347] The title compound was obtained using iso-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 430 (M+H)⁺.

Example 71

[0348] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0349] The title compound was obtained using iso-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 72

[0350] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid isobutyl-amide

[0351] The title compound was obtained using iso-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 73

[0352] Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid isobutyl-amide

[0353] The title compound was obtained using iso-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 425 (M+H)⁺.

Example 74

[0354] Butyl-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid Isobutyl-amide

[0355] The title compound was obtained using iso-butylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 411 (M+H)⁺.

Example 75

[0356] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0357] The title compound was obtained using isobutylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 76

[0358] Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0359] The title compound was obtained using iso-butylamine as R¹R²NH, isobutylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 77

[0360] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0361] The title compound was obtained using iso-butylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(n)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 425 (M+H)⁺.

Example 78

[0362] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0363] The title compound was obtained using iso-butylamine as R¹R²NH, 2-(4-methoxyphenyl)ethylamine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 503 (M+H)⁺.

Example 79

[0364] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0365] The title compound was obtained using iso-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 80

[0366] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0367] The title compound was obtained using iso-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 81

[0368] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0369] The title compound was obtained using iso-butylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(n)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 82

[0370] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0371] The title compound was obtained using iso-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 83

[0372] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0373] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 458 (M+H)⁺.

Example 84

[0374] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0375] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 85

[0376] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0377] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 484 (M+H)⁺.

Example 86

[0378] 4-[4-Isobutylcarbamoyl-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0379] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 420 (M+H)⁺.

Example 87

[0380] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0381] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 439 (M+H)⁺.

Example 88

[0382] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0383] The title compound was obtained using iso-butylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 89

[0384] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0385] The title compound was obtained using iso-butylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 428 (M+H)⁺.

Example 90

[0386] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0387] The title compound was obtained using iso-butylamine as R¹R²NH, methoxyethylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 400 (M+H)⁺.

Example 91

[0388] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0389] The title compound was obtained using iso-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 92

[0390] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0391] The title compound was obtained using iso-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 450 (M+H)⁺.

Example 93

[0392] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0393] The title compound was obtained using iso-butylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 449 (M+H)⁺.

Example 94

[0394] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0395] The title compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 95

[0396] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0397] The title compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(n)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 520 (M+H)⁺.

Example 96

[0398] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0399] The title compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 489 (M+H)⁺.

Example 97

[0400] 4-[4-Isobutylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0401] The title compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 98

[0402] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0403] The tide compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 475 (M+H)⁺.

Example 99

[0404] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0405] The tide compound was obtained using iso-butylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 462 (M+H)⁺.

Example 100

[0406] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0407] The title compound was obtained using iso-butylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 442 (M+H)⁺.

Example 101

[0408] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0409] The title compound was obtained using iso-butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 102

[0410] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0411] The title compound was obtained using iso-butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 103

[0412] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0413] The title compound was obtained using iso-butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 104

[0414] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Isobutyl-amide

[0415] The title compound was obtained using iso-butylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 105

[0416] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-Carboxylic Acid allylamide

[0417] The title compound was obtained using allylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 410 (M+H)⁺.

Example 106

[0418] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0419] The title compound was obtained using allylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 440 (M+H)⁺.

Example 107

[0420] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0421] The title compound was obtained using allylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 410 (M+H)⁺.

Example 108

[0422] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic acid allylamide

[0423] The title compound was obtained using allylamine as R¹R²NH, 2-(4-methoxyphenyl)-ethylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 518 (M+H)⁺.

Example 109

[0424] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0425] The title compound was obtained using allylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 110

[0426] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Allylamide

[0427] The title compound was obtained using allylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 450 (M+H)⁺.

Example 111

[0428] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0429] The title compound was obtained using allylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 480 (M+H)⁺.

Example 112

[0430] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0431] The title compound was obtained using allylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 449 (M+H)⁺.

Example 113

[0432] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

[0433] The title compound was obtained using allylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 422 (M+H)⁺.

Example 114

[0434] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Allylamide

[0435] The title compound was obtained using allylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 438 (M+H)⁺.

Example 115

[0436] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0437] The title compound was obtained using allylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 416 (M+H)⁺.

Example 116

[0438] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0439] The title compound was obtained using allylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 434 (M+H)⁺.

Example 117

[0440] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0441] The title compound was obtained using allylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 433 (M+H)⁺.

Example 118

[0442] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0443] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 478 (M+H)⁺.

Example 119

[0444] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0445] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 474 (M+H)⁺.

Example 120

[0446] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0447] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 504 (M+H)⁺.

Example 121

[0448] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0449] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine Carbothiamide as R⁴C(S)NH₂, MS(ES+) 473 (M+H)⁺.

Example 122

[0450] 4-[4-Allylcarbamoyl-1-(4-methoxy-benzyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0451] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 440 (M+H)+.

Example 123

[0452] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Allylamide

[0453] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 459 (M+H)⁺.

Example 124

[0454] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

[0455] The title compound was obtained using allylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 446 (M+H)⁺.

Example 125

[0456] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Allylamide

[0457] The title compound was obtained using allylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 450 (M+H)⁺.

Example 126

[0458] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Allylamide

[0459] The title compound was obtained using allylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 127

[0460] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0461] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 128

[0462] Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0463] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, butylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 129

[0464] Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

[0465] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, butylamine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 130

[0466] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0467] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 131

[0468] Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0469] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 132

[0470] Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0471] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 133

[0472] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0473] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 438 (M+H)⁺.

Example 134

[0474] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0475] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 506 (M+H)⁺.

Example 135

[0476] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0477] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 505 (M+H)⁺.

Example 136

[0478] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0479] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 478 (M+H)⁺.

Example 137

[0480] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0481] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 138

[0482] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0483] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 139

[0484] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

[0485] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 524 (M+H)⁺.

Example 140

[0486] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0487] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 493 (M+H)⁺.

Example 141

[0488] 4-[4-(Cyclohexylmethyl-carbamoyl)-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0489] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate, MS(ES+) 460 (M+H)⁺.

Example 142

[0490] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0491] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfirylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂. xx479

Example 143

[0492] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0493] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 144

[0494] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0495] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 472 (M+H)⁺.

Example 145

[0496] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0497] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 468 (M+H)⁺.

Example 146

[0498] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0499] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 147

[0500] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0501] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 467 (M+H)⁺.

Example 148

[0502] 4-[4-(Cyclohexylmethyl-carbamoyl)-1-(2-methoxy-ethyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0503] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 434 (M+H)⁺.

Example 149

[0504] 1-(2-Methoxy-ethyl)-2methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3carboxylic Acid Cyclohexylmethyl-amide

[0505] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 453 (M+H)⁺.

Example 150

[0506] 1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0507] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 440 (M+H)⁺.

Example 151

[0508] 1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylmethyl-amide

[0509] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 2-(1-cyclohexenyl)ethylamine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 517 (M+H)⁺.

Example 152

[0510] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0511] The tide compound was obtained using aminomethylcyclohexane as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 153

[0512] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0513] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 534 (M+H)⁺.

Example 154

[0514] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0515] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 530 (M+H)⁺.

Example 155

[0516] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0517] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 529 (M+H)⁺.

Example 156

[0518] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0519] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 486 (M+H)⁺.

Example 157

[0520] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0521] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 158

[0522] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0523] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 512 (M+H)⁺.

Example 159

[0524] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0525] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 481 (M+H)⁺.

Example 160

[0526] 4-[4-(Cyclohexylmethyl-carbamoyl)-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0527] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 448 (M+H)⁺.

Example 161

[0528] 1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0529] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, methoxyethylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 162

[0530] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0531] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 506 (M+H)⁺.

Example 163

[0532] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0533] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 505 (M+H)⁺.

Example 164

[0534] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylmethyl-amide

[0535] The title compound was obtained using aminomethylcyclohexane as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 578 (M+H)⁺.

Example 165

[0536] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0537] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 166

[0538] 4-{1-Isobutyl-5-methyl-4-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrrol-2-yl}-thiazole-2-carboxylic acid ethyl ester

[0539] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 420. (M+H)⁺.

Example 167

[0540] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

[0541] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 168

[0542] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0543] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 169

[0544] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

[0545] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 170

[0546] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0547] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 524 (M+H)⁺.

Example 171

[0548] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0549] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 493 (M+H)⁺.

Example 172

[0550] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0551] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 173

[0552] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

[0553] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 486 (M+H)⁺.

Example 174

[0554] Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0555] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 175

[0556] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(2-methoxy-ethyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0557] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 455 (M+H)⁺.

Example 176

[0558] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0559] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 177

[0560] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0561] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 478 (M+H)⁺.

Example 178

[0562] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0563] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 477 (M+H)⁺.

Example 179

[0564] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

[0565] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and thioacetamide as R⁴C(S)NH₂, MS(ES+) 426 (M+H)⁺.

Example 180

[0566] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0567] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 522 (M+H)⁺.

Example 181

[0568] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0569] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 518 (M+H)⁺.

Example 182

[0570] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0571] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 548 (M+H)⁺.

Example 183

[0572] 4-{1-(4-Methoxy-benzyl)-5-methyl-4-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-1H-pyrrol-2-yl}-thiazole-2-carboxylic Acid Ethyl Ester

[0573] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 484 (M+H)⁺.

Example 184

[0574] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0575] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 503 (M+H)⁺.

Example 185

[0576] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0577] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 490 (M+H)⁺.

Example 186

[0578] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0579] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 469 (M+H)⁺.

Example 187

[0580] 1-(3-Methoxy-propyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0581] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 455 (M+H)⁺.

Example 188

[0582] 1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0583] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 442 (M+H)⁺.

Example 189

[0584] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0585] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 190

[0586] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0587] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 191

[0588] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (tetrahydro-furan-2-ylmethyl)-amide

[0589] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 493 (M+H)⁺.

Example 192

[0590] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide

[0591] The title compound was obtained using tetrahydrofurfurylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 561 (M+H)⁺.

Example 193

[0592] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0593] The title compound was obtained using methoxyethylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 428 (M+H)⁺.

Example 194

[0594] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0595] The title compound was obtained using methoxyethylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 472 (M+H)⁺.

Example 195

[0596] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0597] The title compound was obtained using methoxyethylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 468 (M+H)⁺.

Example 196

[0598] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0599] The tide compound was obtained using methoxyethylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 197

[0600] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0601] The tide compound was obtained using methoxyethylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 440 (M+H)⁺.

Example 198

[0602] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0603] The title compound was obtained using methoxyethylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 199

[0604] 1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0605] The title compound was obtained using methoxyethylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 430 (M+H)⁺.

Example 200

[0606] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

[0607] The title compound was obtained using methoxyethylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 201

[0608] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0609] The title compound was obtained using methoxyethylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 452 (M+H)⁺.

Example 202

[0610] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0611] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 203

[0612] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0613] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 492 (M+H)⁺.

Example 204

[0614] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

[0615] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 522 (M+H)⁺.

Example 205

[0616] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0617] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 491 (M+H)⁺.

Example 206

[0618] 4-[1-(4-Methoxy-benzyl)-4-(2-methoxy-ethylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic acid ethyl ester

[0619] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 458 (M+H)⁺.

Example 207

[0620] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0621] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 477 (M+H)⁺.

Example 208

[0622] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-methoxy-ethyl)-amide

[0623] The title compound was obtained using methoxyethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 464 (M+H)⁺.

Example 209

[0624] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-methoxy-ethyl)-amide

[0625] The title compound was obtained using methoxyethylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 535 (M+H)⁺.

Example 210

[0626] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0627] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 478 (M+H)⁺.

Example 211

[0628] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0629] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 518 (M+H)⁺.

Example 212

[0630] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0631] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R² NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 517 (M+H)⁺.

Example 213

[0632] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (2-cyclohex-1-enyl-ethyl)-amide

[0633] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, tetrahydrofurfirylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 506 (M+H)⁺.

Example 214

[0634] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0635] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 505 (M+H)⁺.

Example 215

[0636] Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0637] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 491 (M+H)⁺.

Example 216

[0638] 1-(2-Methoxy-ethyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0639] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 465 (M+H)⁺.

Example 217

[0640] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0641] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 501 (M+H)⁺.

Example 218

[0642] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0643] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 541 (M+H)⁺.

Example 219

[0644] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0645] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 527 (M+H)⁺.

Example 220

[0646] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-cyclohex-1-enyl-ethyl)-amide

[0647] The title compound was obtained using 2-cyclohex-1-enyl-ethylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 517 (M+H)⁺.

Example 221

[0648] rac-1-Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0649] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 222

[0650] rac-1-Butyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0651] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 512 (M+H)⁺.

Example 223

[0652] rac-1-Butyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0653] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 481 (M+H)⁺.

Example 224

[0654] rac-4-[1-Butyl-4-(2-ethyl-hexylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0655] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, butylamine as R³—(CH₂)_(n)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 448 (M+H)⁺.

Example 225

[0656] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-isobutyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0657] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 486 (M+H)⁺.

Example 226

[0658] rac-1-Isobutyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0659] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 227

[0660] rac-1-Isobutyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0661] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, isobutylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 512 (M+H)⁺.

Example 228

[0662] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-1-isobutyl-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0663] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 44 (M+H)+0.8

Example 229

[0664] rac-1-Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0665] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 230

[0666] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0667] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 2-(1-cyclohexenyl)ethylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 590 (M+H)⁺.

Example 231

[0668] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-[2-(4-methoxy-phenyl)-ethyl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0669] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 2-(1-cyclohexenyl)ethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 559 (M+H)⁺.

Example 232

[0670] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0671] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 526 (M+H)⁺.

Example 233

[0672] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0673] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 522 (M+H)⁺.

Example 234

[0674] rac-1-Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0675] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 521 (M+H)⁺.

Example 235

[0676] rac-4-[1-Cyclohexylmethyl-4-(2-ethyl-hexylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0677] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 488 (M+H)⁺.

Example 236

[0678] rac-1-Cyclohexylmethyl-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0679] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 507 (M+H)⁺.

Example 237

[0680] rac-1-Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0681] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 494 (M+H)⁺.

Example 238

[0682] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0683] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 514 (M+H)⁺.

Example 239

[0684] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0685] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 510 (M+H)⁺.

Example 240

[0686] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0687] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 540 (M+H)⁺.

Example 241

[0688] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0689] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 509 (M+H)⁺.

Example 242

[0690] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-5-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0691] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 476 (M+H)⁺.

Example 243

[0692] rac-2-Methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0693] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 495 (M+H)⁺.

Example 244

[0694] rac-2-Methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0695] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 245

[0696] rac-1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0697] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 484 (M+H)⁺.

Example 246

[0698] rac-1-(2-Methoxy-ethyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0699] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 514 (M+H)⁺.

Example 247

[0700] rac-1-(2-Methoxy-ethyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0701] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 469 (M+H)⁺.

Example 248

[0702] rac-1-(2-Methoxy-ethyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0703] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 456 (M+H)⁺.

Example 249

[0704] rac-1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0705] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 2-(1-cyclohexenyl)ethylamine as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 533 (M+H)⁺.

Example 250

[0706] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0707] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 510 (M+H)⁺.

Example 251

[0708] rac-1-Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0709] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 506 (M+H)⁺.

Example 252

[0710] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0711] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 505 (M+H)⁺.

Example 253

[0712] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (2-ethyl-hexyl)-amide

[0713] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and thioacetamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 254

[0714] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0715] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 550 (M+H)⁺.

Example 255

[0716] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0717] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 546 (M+H)⁺.

Example 256

[0718] rac-1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0719] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 576 (M+H)⁺.

Example 257

[0720] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0721] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 545 (M+H)⁺.

Example 258

[0722] rac-1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0723] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 531 (M+H)⁺.

Example 259

[0724] rac-1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0725] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 518 (M+H)⁺.

Example 260

[0726] rac-1-(3-Methoxy-propyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0727] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and thioacetamide as R⁴C(S)NH₂, MS(ES+) 406 (M+H)⁺.

Example 261

[0728] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0729] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 262

[0730] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0731] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 528 (M+H)⁺.

Example 263

[0732] rac-4-[4-(2-Ethyl-hexylcarbamoyl)-1-(3-methoxy-propyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0733] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethyl-amine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS (ES+) 564 (M+H)⁺.

Example 264

[0734] rac-1-(3-Methoxy-propyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0735] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, methoxyethylamine as R³— (CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 265

[0736] rac-5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0737] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 526 (M+H)⁺.

Example 266

[0738] rac-5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0739] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 522 (M+H)⁺.

Example 267

[0740] rac-5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0741] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 552 (M+H)⁺.

Example 268

[0742] rac-5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0743] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³— (CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 521 (M+H)⁺.

Example 269

[0744] rac-1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0745] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and thioacetamide as R⁴C(S)NH₂, MS(ES+) 498 (M+H)⁺.

Example 270

[0746] rac-1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-ethyl-hexyl)-amide

[0747] The title compound was obtained using 2-ethyl-hexylamine as R¹R²NH, homoveratrylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 620 (M+H)⁺.

Example 271

[0748] Butyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (3-methoxy-propyl)-amide

[0749] The title compound was obtained using methoxypropylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 442 (M+H)⁺.

Example 272

[0750] Butyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0751] The title compound was obtained using methoxypropylamine as R¹R²NH, butylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 414 (M+H)⁺.

Example 273

[0752] Isobutyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0753] The title compound was obtained using methoxypropylamine as R¹R²NH, isobutylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 414 (M+H)⁺.

Example 274

[0754] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0755] The title compound was obtained using methoxypropylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 486 (M+H)⁺.

Example 275

[0756] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0757] The title compound was obtained using methoxypropylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 276

[0758] Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0759] The title compound was obtained using methoxypropylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 512 (M+H)⁺.

Example 277

[0760] Cyclohexylmethyl-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0761] The title compound was obtained using methoxypropylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 481 (M+H)⁺.

Example 278

[0762] Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0763] The title compound was obtained using methoxypropylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 454 (M+H)⁺.

Example 279

[0764] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0765] The title compound was obtained using methoxypropylamine as R¹R²NH, tetrahydrofurfurylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 280

[0766] 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1-(tetrahydro-furan-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0767] The title compound was obtained using methoxypropylamine as R¹R²NH, tetrahydrofurfurylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 500 (M+H)⁺.

Example 281

[0768] 1-(2-Cyclohex-1-enyl-ethyl)-5-[2-(2-ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0769] The title compound was obtained using methoxypropylamine as R¹R²NH, 2-(1-cyclohexenyl)ethylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 493 (M+H)⁺.

Example 282

[0770] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-furan-2-ylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0771] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 470 (M+H)⁺.

Example 283

[0772] Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0773] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-furylmethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 466 (M+H)⁺.

Example 284

[0774] Furan-2-ylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0775] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-furylmethylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 496 (M+H)⁺.

Example 285

[0776] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-methyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0777] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and thioacetamide as R⁴C(S)NH₂, MS(ES+) 414 (M+H)⁺.

Example 286

[0778] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0779] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 510 (M+H)⁺.

Example 287

[0780] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0781] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. 506

Example 288

[0782] 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0783] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 536 (M+H)⁺.

Example 289

[0784] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0785] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 289 (M+H)⁺.

Example 290

[0786] 4-[1-(4-Methoxy-benzyl)-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0787] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂., MS(ES+) 472 (M+H)⁺.

Example 291

[0788] 1-(4-Methoxy-benzyl)-2-methyl-5-[2-(6-methyl-pyridin-3-yl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0789] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³— (CH₂)_(m)—NH₂ and 6-methyl-pyridine-3-carbothioamide as R⁴C(S)NH₂, MS(ES+) 491 (M+H)⁺.

Example 292

[0790] 1-(4-Methoxy-benzyl)-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (3-methoxy-propyl)-amide

[0791] The title compound was obtained using methoxypropylamine as R¹R²NH, 4-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and pyrazine-2-carbothioamide as R⁴C(S)NH₂, MS(ES+) 478 (M+H)⁺.

Example 293

[0792] 5-[2-(2-Chloro-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0793] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-chloro-phenyl thioamide as R⁴C(S)NH₂, MS(ES+) 486 (M+H)⁺.

Example 294

[0794] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0795] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ES+) 482 (M+H)⁺.

Example 295

[0796] 5-[2-(2-Ethyl-pyridin-4-yl)-thiazol-4-yl]-2-methyl-1-thiophen-2-ylmethyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0797] The title compound was obtained using methoxypropylamine as R¹R²NH, 3-(aminomethyl)thiophene as R³—(CH₂)_(m)—NH₂ and 2-ethyl-4-pyridine carbothiamide as R⁴C(S)NH₂, MS(ES+) 481 (M+H)⁺.

Example 296

[0798] 1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3-methoxy-propyl)-amide

[0799] The title compound was obtained using methoxypropylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and 2-(4-methoxyphenoxy)ethanethioamide as R⁴C(S)NH₂, MS(ES+) 580 (M+H)⁺.

Example 297

[0800] 4-[1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic Acid Ethyl Ester

[0801] The title compound was obtained using methoxypropylamine as R¹R²NH, homoveratrylamine as R³—(CH₂)_(m)—NH₂ and ethylthiooxamate as R⁴C(S)NH₂, MS(ES+) 516 (M+H)⁺.

Example 298

[0802] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid morpholin-4-ylamide

[0803] The title compound was obtained using 1-amino-morpholine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 495.3 (M+H)⁺.

Example 299

[0804] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid piperidin-1-ylamide

[0805] The title compound was obtained using 1-amino-piperidine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 493.4 (M+H)⁺.

Example 300

[0806] 1-(4-Chloro-phenyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid butylamide

[0807] The title compound was obtained using butylamine as R¹R²NH, 4-chloroaniline as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 480.3 (M+H)⁺.

Example 301

[0808] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3,4-dimethoxy-phenyl)-amide

[0809] The title compound was obtained using 3,4-dimethoxy aniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 546.3 (M+H)⁺.

Example 302

[0810] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-nitro-phenyl)-amide

[0811] The title compound was obtained using 2-nitroaniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 531.3 (M+H)⁺.

Example 303

[0812] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-trifluoromethyl-phenyl)-amide

[0813] The title compound was obtained using 4-trifluoromethylaniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 554.3 (M+H)⁺.

Example 304

[0814] N′-{1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carbonyl}-hydrazinecarboxylic Acid Ethyl Ester.

[0815] The title compound was obtained using ethyl carbazate as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 497.4 (M+H)⁺.

Example 305

[0816] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (pyridin-2-ylmethyl)-amide

[0817] The title compound was obtained using 2-(aminomethyl)pyridine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 501.3 (M+H)⁺.

Example 306

[0818] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-chloro-phenyl)-amide

[0819] The title compound was obtained using 4-chloro-aniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 520.3 (M+H)⁺.

Example 307

[0820] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (3,4-dichloro-phenyl)-amide

[0821] The title compound was obtained using 3,4-dichloroaniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 554.3 (M+H)⁺.

Example 308

[0822] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid sec-butylamide

[0823] The title compound was obtained using sec-butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 466.4 (M+H)⁺.

Example 309

[0824] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-morpholin-4-yl-methanone.

[0825] The title compound was obtained using morpholine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 480.3 (M+H)⁺.

Example 310

[0826] Methyl-isoxazole-3-carboxylic acid N′-{1-cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carbonyl}-hydrazide.

[0827] The title compound was obtained using 5-methylisoxazole-3-carbohydrazide as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 534.3 (M+H)⁺.

Example 311

[0828] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone.

[0829] The title compound was obtained using piperidine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 478.3 (M+H)⁺.

Example 312

[0830] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-phenethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0831] The title compound was obtained using butylamine as R¹R²NH, phenethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 474.3 (M+H)⁺.

Example 313

[0832] 1-(2-Cyclohexyl-ethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0833] The title compound was obtained using butylamine as R¹R²NH, 2-cyclohexyl-ethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 480.4 (M+H)⁺.

Example 314

[0834] 1-(3,5-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0835] The title compound was obtained using butylamine as R¹R²NH, 3,5-dimethylbenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 488.3 (M+H)⁺.

Example 315

[0836] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Phenylamide

[0837] The title compound was obtained using aniline as R¹R² NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 486.4 (M+H)⁺.

Example 316

[0838] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-phenyl-butyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0839] The title compound was obtained using butylamine as R¹R²NH, 4-phenylbutylamine as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 502.3 (M+H)⁺.

Example 317

[0840] 1-(1-Ethyl-pyrrolidin-2-ylmethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0841] The title compound was obtained using butylamine as R¹R²NH, 2-(aminomethyl)-1-ethylpyrrolidine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 481.3 (M+H)⁺.

Example 318

[0842] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Amide

[0843] The title compound was obtained using aminomethylcyclohexane as R³—(CH₂)_(n)-NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 410.3 (M+H)⁺.

Example 319

[0844] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-morpholin-4-yl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0845] The title compound was obtained using butylamine as R¹R²NH, 4-(2-aminoethyl)morpholine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 483.3 (M+H)⁺.

Example 320

[0846] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-methyl-thiazol-2-yl)-amide

[0847] The title compound was obtained using 2-amino-4-methylthiazole as R¹R² NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 507.3 (M+H)⁺.

Example 321

[0848] 1-(3-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0849] The title compound was obtained using butylamine as R¹R²NH, 3-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 490.3 (M+H)⁺.

Example 322

[0850] 1-(3,5-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0851] The title compound was obtained using butylamine as R¹R²NH, 3,5-dichloroaniline as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 528.2 (M+H)⁺.

Example 323

[0852] Indan-2-yl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0853] The title compound was obtained using butylamine as R¹R²NH, 2-aminoindane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 486.4 (M+H)⁺.

Example 324

[0854] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid pyrimidin-2-ylamide

[0855] The title compound was obtained using 2-aminopyrimidine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 488.3 (M+H)⁺.

Example 325

[0856] 1-(3,4-Dihydroxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0857] The title compound was obtained using butylamine as R¹R²NH, 3,4-dihydroxybenzylamine as R³—(CH₂)_(n)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 492.3 (M+H)⁺.

Example 326

[0858] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-piperidin-1-yl-propyl)-1H-pyrrole-3-carboxylic acid butylamide

[0859] The title compound was obtained using butylamine as R¹R²NH, 3-piperidino-propylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 495.4 (M+H)⁺.

Example 327

[0860] rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (5-hydroxy-2,2,6-trimethyl-cyclohexylmethyl)-amide

[0861] The title compound was obtained using aminomethylcyclohexane as R³—(CH₂)_(m)-NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 564.4 (M+H)⁺.

Example 328

[0862] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0863] The title compound was obtained using butylamine as R¹R²NH, 3-(trifluoromethoxy)benzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 544.4 (M+H)⁺.

Example 329

[0864] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0865] The title compound was obtained using butylamine as R¹R²NH, 4-(trifluoromethoxy)benzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 544.3 (M+H)⁺.

Example 330

[0866] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-methyl-thiophen-2-ylmethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0867] The title compound was obtained using butylamine as R¹R²NH, (3-methyl-2-thienyl)methylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 480.3 (M+H)⁺.

Example 331

[0868] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(4-nitro-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0869] The title compound was obtained using butylamine as R¹R²NH, 4-nitrobenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 505.4 (M+H)⁺.

Example 332

[0870] Benzhydryl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Butylamide

[0871] The title compound was obtained using butylamine as R¹R²NH, benzhydrylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 536.4 (M+H)⁺.

Example 333

[0872] Benzyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0873] The title compound was obtained using butylamine as R¹R²NH, benzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 560.3 (M+H)⁺.

Example 334

[0874] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-pyridin-2-yl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0875] The title compound was obtained using butylamine as R¹R²NH, 2-(2-aminoethyl)pyridine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 475.3 (M+H)⁺.

Example 335

[0876] {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-pyrrolidin-1-yl-methanone

[0877] The title compound was obtained using pyrrolidine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 464.3 (M+H)⁺.

Example 336

[0878] Cyclohexylmethyl-5-[2-(3,4-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0879] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 3,4-dimethoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 496.4 (M+H)⁺.

Example 337

[0880] Cyclohexylmethyl-5-[2-(2-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0881] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 3,4-dimethoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 466.3 (M+H)⁺.

Example 338

[0882] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethyl-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0883] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-trifluoromethylphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 504.2 (M+H)⁺.

Example 339

[0884] Cyclohexylmethyl-5-[2-(3-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0885] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 3-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 466.3 (M+H)⁺.

Example 340

[0886] 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0887] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 1,3-benzodioxole-5-carbothiamide as R⁴C(S)NH₂, MS(ISP) 480.3 (M+H)⁺.

Example 341

[0888] Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0889] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-fluorophenyl thioamide as R⁴C(S)NH₂, MS(ISP) 454.3 (M+H)⁺.

Example 342

[0890] Cyclohexylmethyl-5-[2-(2-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0891] The tide compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2-fluorophenyl thioamide as R⁴C(S)NH₂, MS(ISP) 454.3 (M+H)⁺.

Example 343

[0892] Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic Acid Butylamide

[0893] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-(trifluoromethoxy)phenyl thioamide as R⁴C(S)NH₂, MS(ISP) 520.3 (M+H)⁺.

Example 344

[0894] Cyclohexylmethyl-5-[2-(3,5-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0895] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 3,5-dimethoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 496.4 (M+H)⁺.

Example 345

[0896] Cyclohexylmethyl-2-methyl-5-(2-m-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0897] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 3-methylphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 450.3 (M+H)⁺.

Example 346

[0898] Cyclohexylmethyl-2-methyl-5-(2′-methyl-[2,4′]bithiazolyl-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0899] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³— (CH₂)_(m)—NH₂ and 2-methyl-1,3-thiazole-4-carbothioamide as R⁴C(S)NH₂, MS(ISP) 457.3 (M+H)⁺.

Example 347

[0900] Cyclohexylmethyl-5-[2-(4-ethyl-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0901] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(n)—NH₂ and 4-ethylphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 464.3 (M+H)⁺.

Example 348

[0902] 5-[2-(4-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0903] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-chlorophenyl thioamide as R⁴C(S)NH₂, MS(ISP) 470.3 (M+H)⁺.

Example 349

[0904] 5-[2-(4-tert-Butyl-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0905] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-tertbutylphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 492.4 (M+H)⁺.

Example 350

[0906] Cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0907] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2,3-dihydrobenzo[b]furan-5-carbothioamide as R⁴C(S)NH₂, MS(ISP) 478.3 (M+H)⁺.

Example 351

[0908] Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0909] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methylphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 450.3 (M+H)⁺.

Example 352

[0910] Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0911] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 6-methoxy-nicotamide as R⁴C(S)NH₂, MS(ISP) 467.3 (M+H)⁺.

Example 353

[0912] Cyclohexylmethyl-5-[2-(2,4-dichloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0913] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 2,4-dichlorophenyl thioamide as R⁴C(S)NH₂, MS(ISP) 504.2 (M+H)⁺.

Example 354

[0914] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Pentylamide

[0915] The title compound was obtained using pentylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 481.3 (M+H)⁺.

Example 355

[0916] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Propylamide

[0917] The title compound was obtained using propylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 452.3 (M+H)⁺.

Example 356

[0918] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclohexylamide

[0919] The title compound was obtained using cyclohexylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 492.3 (M+H)⁺.

Example 357

[0920] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclopentylamide

[0921] The title compound was obtained using cyclopentylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 478.3 (M+H)⁺.

Example 358

[0922] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Cyclopropylamide

[0923] The title compound was obtained using cyclopropylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 450.3 (M+H)⁺.

Example 359

[0924] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide

[0925] The title compound was obtained using cyclobutylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 464.3 (M+H)⁺.

Example 360

[0926] (trans) rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (2-hydroxy-cyclopentyl)-amide

[0927] The title compound was obtained using trans-2-aminocyclopentanol as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 494.3 (M+H)⁺.

Example 361

[0928] 1-(4-Chloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0929] The title compound was obtained using butylamine as R¹R²NH, 4-chloroaniline as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 494.2 (M+H)⁺.

Example 362

[0930] 1-(3,4-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0931] The title compound was obtained using butylamine as R¹R²NH, 3,4-dichloroaniline as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as —R⁴C(S)NH₂, MS(ISP) 527.2 (M+H)⁺.

Example 363

[0932] 1-(4-Chloro-3-trifluoromethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0933] The title compound was obtained using butylamine as R¹R²NH, 3-trifluoromethyl,4-chloro aniline as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 562.2 (M+H)⁺.

Example 364

[0934] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0935] The title compound was obtained using butylamine as R¹R²NH, 3,4-dimethylbenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 488.3 (M+H)⁺.

Example 365

[0936] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-methyl-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0937] The title compound was obtained using butylamine as R¹R²NH, 2-methylbenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 474.3 (M+H)⁺.

Example 366

[0938] 1-(3,4-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0939] The title compound was obtained using butylamine as R¹R²NH, 3,4-dimethoxybenzyl-amine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 520.4 (M+H)⁺.

Example 367

[0940] 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0941] The title compound was obtained using butylamine as R¹R²NH, 2,4-dimethoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 520.3 (M+H)⁺.

Example 368

[0942] 1-(3,5-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0943] The title compound was obtained using butylamine as R¹R²NH, 3,5-methoxybenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 520.3 (M+H)⁺.

Example 369

[0944] Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0945] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-hydroxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 452.3 (M+H)⁺.

Example 370

[0946] 1-(4-Isopropyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0947] The title compound was obtained using butylamine as R¹R²NH, 4-isopropylbenzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 502.3 (M+H)⁺.

Example 371

[0948] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0949] The title compound was obtained using butylamine as R¹R²NH, 2-(aminomethyl)pyridine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂, MS(ISP) 461.3 (M+H)⁺.

Example 372

[0950] Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid (4-trifluoromethoxy-phenyl)-amide

[0951] The title compound was obtained using 4-(trifluoromethoxy)aniline as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. MS(ISP) 569.6 (M+H)⁺.

Example 373

[0952] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3,4,5-trimethoxy-benzyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0953] The title compound was obtained using butylamine as R¹R²NH, 3,4,5-trimethoxy-benzylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. MS(ISP) 549.2 (M+H)⁺.

Example 374

[0954] 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(2-p-tolyl-ethyl)-1H-pyrrole-3-carboxylic Acid Butylamide

[0955] The title compound was obtained using butylamine as R¹R²NH, 2-(p-tolyl)ethylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. MS(ISP) 487.6 (M+H)⁺.

Example 375

[0956] Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0957] The title compound was obtained using butylamine as R¹R²NH, aminomethylcyclohexane as R³—(CH₂)_(m)—NH₂ and cyclohexane carbothioamide as R⁴C(S)NH₂. MS(ISP) 441.68 (M+H)⁺.

Example 376

[0958] Cyclohexyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-carboxylic Acid Cyclopropylmethyl-amide

[0959] The title compound was obtained using cyclopropylmethylamine as R¹R²NH, cyclohexylamine as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. MS(ISP) 450.3 (M+H)⁺.

Example 377

[0960] rac 1-(5-Hydroxy-1,3,3-trimethyl-cyclohexylmethyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic Acid Butylamide

[0961] The title compound was obtained using butylamine as R¹R²NH, 3-aminomethyl-3,5,5-trimethyl-cyclohexanol as R³—(CH₂)_(m)—NH₂ and 4-methoxyphenyl thioamide as R⁴C(S)NH₂. MS(ISP) 524.4 (M+H)⁺.

Galenical Examples Example A

[0962] Film coated tablets containing the following ingredients can be manufactured in a conventional manner: Ingredients Per tablet Kernel: Compound of formula (I) 10.0 mg  200.0 mg  Microcrystalline cellulose 23.5 mg  43.5 mg  Lactose hydrous 60.0 mg  70.0 mg  Povidone K30 12.5 mg  15.0 mg  Sodium starch glycolate 12.5 mg  17.0 mg  Magnesium stearate 1.5 mg 4.5 mg (Kernel Weight) 120.0 mg  350.0 mg  Film Coat: Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg Polyethylene glycol 6000 0.8 mg 1.6 mg Talc 1.3 mg 2.6 mg Iron oxyde (yellow) 0.8 mg 1.6 mg Titan dioxide 0.8 mg 1.6 mg

[0963] The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution/suspension of the above mentioned film coat.

Example B

[0964] Capsules containing the following ingredients can be manufactured in a conventional manner: Ingredients Per capsule Compound of formula (I) 25.0 mg Lactose 150.0 mg  Maize starch 20.0 mg Talc  5.0 mg

[0965] The components are sieved and mixed and filled into capsules of size 2.

Example C

[0966] Injection solutions can have the following composition: Compound of formula (I) 3.0 mg Polyethylene glycol 400 150.0 mg Acetic acid q.s.ad pH 5.0 Water for injection solutions ad 1.0 ml

[0967] The active ingredient is dissolved in a mixture of Polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by addition of acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized. 

What is claimed is:
 1. A compound of formula (I)

wherein R¹ is hydrogen, or lower alkyl; R² is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a); or R¹ and R² together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing one or two further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; R^(2a) is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R³ is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH₂)_(n)—R^(3a); R^(3a) is cycloalkyl, which may optionally be fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R⁴ is lower alkyl, lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH₂)_(p)—O— or —(CH₂)₂—O—; R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl; R⁷ is hydrogen, lower alkyl or halogen; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
 2. The compound according to claim 1, wherein R¹ is hydrogen.
 3. The compound according to any of claim 1, wherein R² is lower alkyl or a residue —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a).
 4. The compound according to claim 1, wherein R² is a residue —(CH₂)_(m)—R^(a) or —NHC(O)—R^(a).
 5. The compound according to claim 4, wherein R^(2a) is a cycloalkyl residues with three to six carbon atoms, which may optionally be mono-or tetra-substituted, independently, by lower alkyl and/or hydroxy.
 6. The compound according to claim 4, wherein R^(2a) is cyclohexenyl.
 7. The compound according to claim 4, wherein R^(2a) is an unsubstituted 5-membered monovalent saturated heterocyclic ring containing one or two heteroatoms independently selected from nitrogen and oxygen.
 8. The compound according to claim 7, wherein R^(2a) is piperidinyl, morpholino or tetrahydrofuranyl.
 9. The compound according to claim 4, wherein R^(2a) is a 5-or 6-membered monovalent heterocyclic ring containing one or two heteroatoms independently selected from nitrogen and sulfur, said heteroaromatic ring bein optionally substituted by lower alkyl.
 10. The compound according to claim 9, wherein R^(2a) is pyridinyl, pyrimidinyl, thiazolyl or isoxazolyl, optionally substituted by lower alkyl.
 11. The compound according to claim 4, wherein R², is a phenyl residue which is optionally mono-or di-substituted, independently, by lower alkoxy, halogen, halogenated lower alkyl, halogenated lower alkoxy or nitro.
 12. The compound according to claim 1, wherein m is 0 or
 1. 13. The compound according to claim 1, wherein R¹ and R² together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing an oxygen atom in the ring.
 14. The compound according to claim 13, wherein R¹ and R² together with the nitrogen atom to which they are attached are unsubstituted pyrrolidinyl, piperidinyl or morpholino.
 15. The compound according to claim 1, wherein R³ is a residue —(CH₂)_(n)—R^(3a).
 16. The compound according to claim 15, wherein R^(3a) is cycloalkyl fused to a phenyl ring.
 17. The compound according to claim 15, wherein R^(3a) is an unsubstituted cycloalkyl residue with five or six carbon atoms.
 18. The compound according to claim 15, wherein R³, is a 5-or 6-memberd heterocyclic ring containing one or two heteroatoms independently selected from nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by lower alkyl.
 19. The compound according to claim 15, wherein R^(3a) is a 5-or 6-membered heteroaromatic ring containing one heteroatom selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-substituted by lower alkyl.
 20. The compound according to claim 15, wherein R^(3a) is phenyl optionally mono-or di-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, halogenated lower alkyl, halogenated lower alkoxy or nitro.
 21. The compound according to claim 15, wherein n is 1 or
 2. 22. The compound according to claim 1, wherein R⁴ is unsubstituted cyclohexyl.
 23. The compound according to claim 1, wherein R⁴ is a 5-or 6-membered heteroaromatic ring containing one or two heteroatoms independently selected from nitrogen and sulfur, said heteroaromatic ring being optionally mono-substituted by lower alkyl.
 24. The compound according to claim 1, wherein R⁴ is phenyl mono-or di-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, halogenated lower alkyl, halogenated lower alkoxy or nitro.
 25. The compound according to claim 1, wherein two adjacent substituents of a phenyl residue R⁴ together are —O—(CH₂)—O— or —(CH₂)₂—O—.
 26. The compound according to claim 1, selected from the group consisting of: 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid butylamide, 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1 H-pyrrole-3-c arboxylic acid sec-butylamide, rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenoxymethyl)-thiazol-4-yl]-2-methyl-1 H-pyrr ole-3-carboxylic acid sec-butylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide, 1-Furan-2-ylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid isobutyl-amide, 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid isobutyl-amide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid allylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-c arboxylic acid cyclohexylmethyl-amide, 1-Cyclohexylmethyl-2-methyl-5-(2-pyrazin-2-yl-thiazol-4-yl)-1H-pyrrole-3-carboxy lic acid cyclohexylmethyl-amide, or a pharmaceutically acceptable salt thereof.
 27. The compound according to claim 1, selected from the group consisting of: 1-(4-Methoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3 carboxylic acid cyclohexylmethyl-amide, 5-[2-(4-Methoxy-phenoxymethyl)-thiazol-4-yl]-1-(3-methoxy-propyl)-2-methyl-1H-py rrole-3-carboxylic acid cyclohexylmethyl-amide, 4-[1-[2-(3,4-Dimethoxy-phenyl)-ethyl]-4-(3-methoxy-propylcarbamoyl)-5-methyl-1H-pyrrol-2-yl]-thiazole-2-carboxylic acid ethyl ester, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide, N′-{1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carbonyl}-hydrazinecarboxylic acid ethyl ester, rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide, {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-piperidin-1-yl-methanone, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid phenylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pyrimidin-2-ylamide, rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (5-hydroxy-2,2,6-trimethyl-cyclohexylmethyl)-amide, or a pharmaceutically acceptable salt thereof.
 28. The compound according to claim 1, selected from the group consisting of: 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-(3-trifluoromethoxy-benzyl)-1H-pyrrole-3-carboxylic acid butylamide, 1-Benzyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, {1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrol-3-yl}-pyrrolidin-1-yl-methanone, 1-Cyclohexylmethyl-5-[2-(3,4-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(3-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 5-(2-Benzo [1,3] dioxol-5-yl-thiazol-4-yl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(4-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(2-fluoro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-2-methyl-5-[2-(4-trifluoromethoxy-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(3,5-dimethoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, or a pharmaceutically acceptable salt thereof.
 29. The compound according to claim 1, selected from the group consisting of: 1-Cyclohexylmethyl-2-methyl-5-(2-m-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-2-methyl-5-(2′-methyl-[2,4′] bithiazolyl-4-yl)-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(4-ethyl-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 5-[2-(4-Chloro-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 5-[2-(4-tert-Butyl-phenyl)-thiazol-4-yl]-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(2,3-dihydro-benzofuran-5-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-2-methyl-5-(2-p-tolyl-thiazol-4-yl)-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(6-methoxy-pyridin-3-yl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(2,4-dichloro-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-2-methyl-5-[2-(4-nitro-phenyl)-thiazol-4-yl]-1H-pyrrole-3-carboxylic acid butylamide, or a pharmaceutically acceptable salt thereof.
 30. The compound according to claim 1, selected from the group consisting of: 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid pentylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid propylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide, 1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide, (trans) rac-1-Cyclohexylmethyl-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-cyclopentyl)-amide, or a pharmaceutically acceptable salt thereof.
 31. The compound according to claim 1, selected from the group consisting of: 1-(4-Chloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-(3,4-Dichloro-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-(3,4-Dimethyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-(3,4-Dimethoxy-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-[2-(4-hydroxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 1-(4-Isopropyl-benzyl)-5-[2-(4-methoxy-phenyl)-thiazol-4-yl]-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, 5-[2-(4-Methoxy-phenyl)-thiazol-4-yl]-2-methyl-1-pyridin-2-ylmethyl-1H-pyrrole-3-carboxylic acid butylamide, 1-Cyclohexylmethyl-5-(2-cyclohexyl-thiazol-4-yl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, or a pharmaceutically acceptable salt thereof.
 32. A process for the manufacture of compounds of formula (I) as defined in claim 1, which process comprises reaction of an enamine of formula A:

wherein R¹, R², R³, R⁵ and m are as defined claim 1; with an alfa-bromoketone of formula B:

wherein R⁴, R⁶ and R⁷ are as defined claim
 1. 33. A compound manufactured by a process according to claim
 32. 34. A pharmaceutical composition comprising a compound of formula (I)

wherein R¹ is hydrogen, or lower alkyl; R² is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(a); or R¹ and R² together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing one or two further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; R^(2a) is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R³ is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH₂)_(n)—R^(3a); R³, is cycloalkyl, which may optionally be fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R⁴ is lower alkyl, lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH₂)_(p)—O— or —(CH₂)₂—O—; R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl; R⁷ is hydrogen, lower alkyl or halogen; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier and/or adjuvant.
 35. A method for the treatment and/or prophylaxis of a disease associated with the modulation of the CB 1 receptor comprising administering to a patient in need thereof, a therapeutically effective amount of a compound of formula (I)

wherein R¹ is hydrogen, or lower alkyl; R² is hydrogen, lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, lower alkoxycarbonylamino, —(CH₂)_(m)—R^(2a) or —NHC(O)—R^(2a); or R¹ and R² together with the nitrogen atom to which they are attached form a 5-or 6-membered, saturated heterocyclic ring optionally containing one or two further heteroatom(s) independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; R^(2a) is cycloalkyl, optionally mono-, di-, tri-or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R³ is lower alkyl, lower alkenyl, lower alkoxy-lower alkyl, di-phenyl-lower alkyl, or —(CH₂)_(n)—R^(3a); R^(3a) is cycloalkyl, which may optionally be fused to a phenyl ring; or cycloalkyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; cycloalkenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; R⁴ is lower alkyl, lower alkoxycarbonyl; cycloalkyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; phenoxy-lower alkyl, wherein the phenyl moiety may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by, hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or two adjacent substituents of the said phenyl residue together are —O—(CH₂)_(p)—O— or —(CH₂)₂—O—; R⁵ and R⁶ are each independently selected from hydrogen, lower alkyl, halogen or fluorinated methyl; R⁷ is hydrogen, lower alkyl or halogen; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
 5. 36. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of psychic disorders, anxiety, psychosis, schizophrenia, depression, abuse of psychotropes, abuse and/or dependence of a substance, alcohol dependency, nicotine dependency, neuropathies, migraine, stress, epilepsy, dyskinesias, Parkinson's disease, amnesia, cognitive disorders, senile dementia, Alzheimer's disease, eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), gastrointestinal diseases, vomiting, diarrhea, urinary disorders, cardiovascular disorders, infertility disorders, inflammations, infections, cancer, neuroinflammation, in particular in atherosclerosis, or the Guillain-Barre syndrome, viral encephalitis, cerebral vascular incidents and cranial trauma.
 37. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, abuse and/or dependence of a substance, alcohol dependency, nicotine dependency.
 38. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), abuse and/or dependence of a substance, alcohol dependency and nicotine dependency.
 39. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is obesity. 